3.50

7.16% -0.27

Ironwood Pharmaceuticals Inc (IRWD)

Overview News Price History Option Chain Financials Discussions Forecast

Ironwood Pharmaceuticals Inc stock is traded at $3.50, with a volume of 2.53M. It is down -7.16% in the last 24 hours and down -16.07% over the past month. Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Previous Close:

$3.77

Open:

$3.73

24h Volume:

2.53M

Relative Volume:

1.32

Market Cap:

$578.34M

Revenue:

$361.51M

Net Income/Loss:

$102.18M

P/E Ratio:

5.8587

EPS:

0.5974

Net Cash Flow:

$112.21M

1W Performance:

-8.38%

1M Performance:

-16.07%

6M Performance:

-19.17%

1Y Performance:

+125.81%

1-Day Range:

$3.48

$3.73

1-Week Range:

$3.48

$3.87

52-Week Range:

$1.43

$5.78

Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile

Name

Ironwood Pharmaceuticals Inc

Sector

Healthcare (1052)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

617-621-7722

Address

100 SUMMER STREET, SUITE 2300, BOSTON, MA

Employee

100

Twitter

@ironwoodpharma

Next Earnings Date

2026-11-09

Latest SEC Filings

IRWD's Discussions on Twitter

Compare IRWD vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IRWD Ironwood Pharmaceuticals Inc	3.50	578.34M	361.51M	102.18M	112.21M	0.5974
TAK Takeda Pharmaceutical Co Adr	19.67	62.84B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.50	48.40B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.13	44.55B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.38	32.80B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	533.12	22.87B	3.17B	1.29B	1.01B	27.09

Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Apr-15-25	Downgrade	Jefferies	Buy → Hold
Apr-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Sep-09-24	Initiated	Leerink Partners	Market Perform
Aug-08-24	Downgrade	CapitalOne	Overweight → Equal Weight
Jan-17-24	Initiated	Craig Hallum	Buy
Dec-14-23	Initiated	Wells Fargo	Overweight
Nov-09-23	Initiated	Jefferies	Buy
Sep-28-23	Initiated	JMP Securities	Mkt Outperform
Sep-02-22	Initiated	CapitalOne	Overweight
Apr-22-22	Initiated	Piper Sandler	Overweight
Sep-30-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-17-20	Initiated	Northland Capital	Outperform
Jul-10-19	Resumed	Credit Suisse	Neutral
Mar-27-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-25-19	Upgrade	H.C. Wainwright	Sell → Neutral
Jan-24-19	Upgrade	JP Morgan	Underweight → Neutral
Nov-07-18	Downgrade	Credit Suisse	Outperform → Neutral
Nov-07-18	Downgrade	JP Morgan	Neutral → Underweight
Jul-23-18	Initiated	H.C. Wainwright	Sell
May-09-18	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-05-18	Downgrade	BofA/Merrill	Buy → Underperform
Dec-06-17	Downgrade	Mizuho	Buy → Neutral
Jul-21-17	Downgrade	JP Morgan	Overweight → Neutral
May-03-17	Initiated	Wells Fargo	Outperform
Apr-07-17	Reiterated	Mizuho	Buy
Feb-22-17	Reiterated	Barclays	Equal Weight
Nov-04-16	Reiterated	Mizuho	Buy
Oct-24-16	Reiterated	Wedbush	Neutral
Oct-10-16	Reiterated	Mizuho	Buy
Sep-27-16	Reiterated	WallachBeth	Hold

View All

Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News

Oct 07, 2026

Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research

Oct 07, 2026

Sep 30, 2026

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research

Sep 30, 2026

Sep 27, 2026

Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com Australia

Sep 27, 2026

Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com India

Sep 27, 2026

Sep 23, 2026

83,306 shares to cover taxes: Ironwood Pharmaceuticals (IRWD) ex-officer proposes a sale - Stock Titan

Sep 23, 2026

Sep 17, 2026

Ironwood Pharmaceuticals Director Alexander J. Denner Awarded 3,694 Shares Under Compensation Policy - Kalkine Media

Sep 17, 2026

Sep 11, 2026

Ironwood: Medicare Is Not The Problem I Thought It Was - Seeking Alpha

Sep 11, 2026

Sep 10, 2026

Ironwood Pharmaceuticals at Wells Fargo conference: linzess rebound drives turnaround - Investing.com Canada

Sep 10, 2026

Ironwood Pharmaceuticals at Wells Fargo conference: linzess rebound drives turnaround - Investing.com UK

Sep 10, 2026

Sep 09, 2026

IRWD Stock Price, Quote & News - Syfe

Sep 09, 2026

Sep 04, 2026

IRWD stock gains as Wells Fargo conference spotlight shifts to cash flow - ad-hoc-news.de

Sep 04, 2026

Sep 03, 2026

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance

Sep 03, 2026

Aug 30, 2026

Ironwood Pharmaceuticals Inc. Class A (IRWD) Peer Comparison – Compare with Others - Value Research

Aug 30, 2026

Ironwood Pharmaceuticals (IRWD) Slips 2.6% as Shares Approach Key Support at $3.92Backspread Trade - vinanet.vn

Aug 30, 2026

Ironwood Pharmaceuticals (IRWD) Slips 2.59% to $4.13: Analyzing Key Support and Resistance LevelsETF Flow - dars.gov.et

Aug 30, 2026

Aug 28, 2026

Ironwood Pharmaceuticals Inc. Class A (IRWD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 28, 2026

Aug 26, 2026

Ironwood Pharmaceuticals: High Dependence On Its Next Trial (NASDAQ:IRWD) - Seeking Alpha

Aug 26, 2026

Aug 20, 2026

Ironwood (IRWD) Results Versus Estimates: EPS Does Not Reach the Reported Estimate for the Current Session; Market Move: The Market Price Moves 1.16% Higher in Latest TradingEarnings Yield Analysis - vinanet.vn

Aug 20, 2026

Aug 17, 2026

Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportRSI Oversold Picks - vinanet.vn

Aug 17, 2026

Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportValue ETF - dars.gov.et

Aug 17, 2026

Aug 16, 2026

Jeffrey Silber Net Worth (2026) - GuruFocus

Aug 16, 2026

Bank of America Corp DE Sells 2,838,753 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat

Aug 16, 2026

Aug 15, 2026

Ironwood Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo

Aug 15, 2026

Ironwood Pharmaceuticals (IRWD) Q2 2026 Earnings: EPS Misses Estimates, Stock Climbs 5.64%Dividend Growth Analysis - vinanet.vn

Aug 15, 2026

Aug 14, 2026

Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake - stocktitan.net

Aug 14, 2026

Aug 11, 2026

Dimensional Fund Advisors LP Raises Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat

Aug 11, 2026

Aug 10, 2026

Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownTime to Sell? - MarketBeat

Aug 10, 2026

Aug 08, 2026

Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Aug 08, 2026